Cassava Sciences | PTIE - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Abbott USD 52.13B 1.3B 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.21B 573.5M 2025-09
Cara Therapeutics USD 32.93M 41M 2025-06
Cassava Sciences USD 74.4M 7.16M 2025-12
Eisai JPY 889.64B 35.21B 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Geron USD 225.87M 22.83M 2025-12
J&J USD 78.47B 0 2025-09
Merck USD 51.85B 2.79B 2025-09
Novartis USD 46.13B 1.38B 2025-12
Novavax USD -127.75M 28.92M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Roche Holding CHF 33.8B 758M 2025-12